2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow OrsoBio, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo - Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease | Phase 2 | Unknown | OrsoBio, Inc | 30 | 2024-08-12 | 2025-04-03 |
| A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance TLC-3595 Dose 1, TLC-3595 Dose 2, Placebo - Insulin Resistance | Phase 2 | Unknown | OrsoBio, Inc | 76 | 2023-03-08 | 2024-08-20 |
Hypertriglyceridemia (1) · Insulin Resistance (1) · Non-alcoholic Fatty Liver Disease (1)
Mexico (1) · New Zealand (1)